Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Relative Bioavailability of Apixaban (BMS-562247) 0.1 mg Sprinkle Capsules Compared With 0.5 mg Tablets in Healthy Participants

Trial Profile

Relative Bioavailability of Apixaban (BMS-562247) 0.1 mg Sprinkle Capsules Compared With 0.5 mg Tablets in Healthy Participants

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2018

At a glance

  • Drugs Apixaban (Primary)
  • Indications Acute coronary syndromes; Deep vein thrombosis; Pulmonary embolism; Stroke; Thromboembolism; Venous thromboembolism
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 30 Jul 2018 Status changed from recruiting to completed.
    • 08 Jun 2018 Planned End Date changed from 28 May 2018 to 29 Jun 2018.
    • 08 Jun 2018 Planned primary completion date changed from 25 May 2018 to 29 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top